Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Investors

Rgenix is made possible through financing from investors including Novo A/S, Sofinnova Partners, Lepu Holdings, Partnership Fund for New York City, Alexandria Venture Investments, Oceanpine Capital, WuXi AppTec, Conegliano Ventures LP, and Exor Seeds.

novo
sofinnova
lepu medical
Alexandria
Oceanpine logo
Wuxi logo